Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
Cancer patients with a SARS-CoV-2 infection before vaccination had a higher risk of death after a breakthrough infection.
The median cancer-specific survival was 56.5 months.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
Iodine concentration and Hounsfield units were associated with treatment response and survival.
The risk of death from any cause was higher with degarelix.
The seroconversion rate was 92%.
It was previously unknown whether the survival benefits seen with lenvatinib plus pembrolizumab persisted in the long term.
Experts outline benefits and detriments of COVID-19 vaccine mandates.
